Dent Neurologic

Uncategorized

CogMS

CogMS – A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis The present study will investigate the correlation between objective and subjective cognition in multiple sclerosis. The study will also investigate the impact of covariates such as fatigue and depression, the relationship with the Expanded Disability Status Scale (EDSS) and brain volumetrics as […]

CogMS Read More »

Generation HD-2

Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study:   25 Years to 50 Years   (Adult) Sexes Eligible for Study:   All Generation HD-2 Link

Generation HD-2 Read More »

ENVISION

ENVISION Trial  The objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease. What is Alzheimer’s Disease? Alzheimer’s is

ENVISION Read More »

PROSEEK

PROSEEK To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug for people with early-stage Parkinson’s disease (PD). The investigational drug is being studied to see if it can slow the progression of Parkinson’s disease. It is designed to block a

PROSEEK Read More »

NRX- 101

Testing the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in improving symptoms of depression as measured by the total Montgomery Åsberg Depression Rating Scale (MADRS-10) score in patients with bipolar depression and subacute suicidal ideation and behavior (SSIB) which does not require hospitalization.

NRX- 101 Read More »

ADNI4 Trial

ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly

ADNI4 Trial Read More »

Hearing Aid Research

Hearing Aid Research Are you interested in participating in hearing aid research?  Dr. Zhang is collaborating with Dr. Wei Sun at UB and is recruiting people over the age of 18 who have tinnitus and hearing loss. Participants will be compensated for their time. This study will require you to wear hearing aids for 3-4

Hearing Aid Research Read More »

Meniere’s Study

Meniere’s Study Have you been diagnosed with Meniere’s Disease? Do you frequently experience vertigo? If you answered yes to these questions and are over the age of 18, you may qualify for a research study. Qualified participants will receive at no cost: All study-related exams Study drug or placebo (no active ingredient) If you are

Meniere’s Study Read More »

X-TOLE: XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-Label Extension

A clinical research study is underway for people with focal epilepsy currently taking 1-3 anti-epileptic drugs that are still experiencing frequent seizures. Three doses of investigational drug are being studied and some participants will be assigned placebo. All participants will receive active study on the extension study.

X-TOLE: XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-Label Extension Read More »

Scroll to Top